CAR T cell therapy for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has not been cured by at least 4 prior treatments.
- You may be in a second or third complete remission but cannot have a stem cell transplant due to age, other health problems, or no donor.
- If you had a stem cell transplant before and the cancer came back, you may still qualify.
- You have some remaining disease after your first treatment and cannot have a stem cell transplant.
- You are expected to live more than 12 weeks.
- Your kidneys, liver, and blood counts are within certain limits, and you are not pregnant, breastfeeding, or have active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
This study tests a new type of cell therapy, called CAR-T, for people newly diagnosed with myeloma who can't have a stem cell transplant. The therapy uses your own immune cells, changed in a lab to better fight the myeloma cells.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.